Thyroid Cancer

Thyroid cancer is the most common form of endocrine malignancy and its incidence is increasing. Thyroid cancers usually present as painless nodules found upon palpation, and nodules >1 cm should be evaluated as they have a higher potential for being clinically significant cancers. Read More ›

RET is a tyrosine kinase receptor that, when fused with a partner molecule, activates oncogenic activity. RET abnormalities are found in both papillary and medullary thyroid cancers and are promising targets for treatment. Read More ›

Medullary thyroid cancer (MTC) accounts for 5% of all thyroid cancers. The only curative treatment option for MTC is surgery, but understanding of the RET pathway and the development of therapies targeting this pathway may improve outcomes for these patients. Read More ›

Papillary thyroid cancer is the most prevalent thyroid cancer, accounting for 80% of thyroid cancer diagnoses. Prognosis is good for patients with early and aggressive treatment, and the new and emerging therapies targeting the RET pathway may improve outcomes for patients with advanced disease. Read More ›

Among patients with radioiodine-refractory advanced or metastatic thyroid cancer, tyrosine kinase inhibitors are guideline recommended. New RET-specific kinase inhibitors have recently demonstrated positive outcomes for these patients. Read More ›

The thyroid is a butterfly-shaped endocrine gland that produces hormones essential in maintaining normal heart rate, blood pressure, body temperature, and metabolism. Thyroid cancer represents only 2.9% of new cancer cases annually in the United States but occurs approximately 3 times as often in women as in men.1,2 The following information about thyroid cancer may prove helpful. Read More ›

On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020. Read More ›


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: